德琪医药(06996.HK)ATG-010新药上市申请获药监局优先审评
德琪医药(06996.HK)公布,旗下研发的选择性核输出抑制剂ATG-010(Selinexor,又名XPOVIO),其新药上市申请已获得国家药品监督管理局授予优先审评资格,将用於治疗难治复发性多发性骨髓瘤(rrMM)患者。
德琪医药表示,ATG-010作为全球首个获得批准的SINE化合物,已经完成在中国大陆注册临床实验的患者入组,并在过去六个月向包括澳大利亚、韩国及新加坡等在内的5个亚太市场提交了新药上市申请。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.